Auxotrophic, recombinant bcg strain pasteur and use thereof for combating human infections caused by parasites

A technology of auxotrophic strains, applied in anti-infective drugs, bacterial antigen components, recombinant DNA technology, etc., can solve the problem of not providing plasmid stability

Inactive Publication Date: 2012-05-02
FUNDACAO OSWALDO CRUZ FIOCRUZ
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] However, the presence of antibiotic resistance-encoding genes in vivo does not provide a choice for plasmid stability

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Auxotrophic, recombinant bcg strain pasteur and use thereof for combating human infections caused by parasites
  • Auxotrophic, recombinant bcg strain pasteur and use thereof for combating human infections caused by parasites
  • Auxotrophic, recombinant bcg strain pasteur and use thereof for combating human infections caused by parasites

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0017] The present invention relates to the use of the BCGΔleuD strain and the complementary vector pUP410 to obtain a vaccine strain for the control of infections caused by Schistosoma mansoni and related parasites, based on the in vivo expression of Sm14 of Schistosoma mansoni.

[0018] The main purpose of the present invention can be achieved by constructing the expression system of the Sm14 antigen in BCG using auxotrophic complementation as a selectable marker. The expression system used in the present invention was developed by a group consisting of Dr. Johnjoe Mcfadden, Faculty of Biological Sciences, University of Surrey, UK and Dr. Odir Dellagostin, Center for Biotechnology, Pelotas Union University, Brazil, on the subject of the main Developed in a research project for the development of recombinant BCG multiple vaccines and complementary diagnostics for parasitic and epidemic diseases.

[0019] The BCG system using auxotrophic complementation consists and features o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a recombinant BCG vaccine strain of Mycobacterium bovis that expresses the Sm14 antigen of Schistosoma mansoni (BCGr Pasteur delta LeuD / p delta K410-hsp60*-Sm14). The vaccine strain according to the present invention is used for combating infection by parasites, particularly Schistosoma mansoni. The vaccine strain is a leucine-auxotrophic strain derived from the BCG substrain Pasteur, supplemented for leucine after genetic transformation with the construct p delta K410-hsp60*-SM14. The effectiveness of the BCGr Pasteur delta LeuD / p delta K410-hsp60*-Sm14 strain for combating Schistosoma mansoni infection by expressing the recombinant Sm14 antigen in vivo is demonstrated in the present invention.

Description

technical field [0001] The invention relates to a recombinant vaccine strain of Bacillus Calmette-Guerin (BCG) Mycobacterium bovis expressing Schistosoma mansoni Sm14 antigen. The vaccine strains of the present invention are used to control infections caused by parasites, especially Schistosoma mansoni. The vaccine strain of the vaccine is an auxotrophic strain activated by leucine complement obtained from the genetic modification of the Pasteur BCG sub-strain. Background technique [0002] It is estimated that at least 200 million people are infected with one of the five types of schistosomes that affect humans. Additionally, another 600 million are at risk of being affected by this parasite. [0003] Chemotherapy with the anti-anthelmintic drug praziquantel is the main method of control; however, this re-infection rate is high [Al-Sherbiny M, Osman A, Barakat R, El Morshedy H, Bergquist R & Olds R ( 2003). Cellular and humoral responses to Schistosoma mansoni vaccine te...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/76A61P33/10A61P31/06A61P35/00
CPCA61K2039/522A61K2039/523A61K39/002C07K14/43559A61K39/04A61K35/74A61K39/0003A61P31/04A61P31/06A61P33/00A61P33/10A61P33/12A61P35/00A61P37/04Y02A50/30
Inventor 米里亚姆·滕德勒莫妮卡·马格诺·比拉尔热拉尔多·罗得里格斯·加西亚·阿尔马道格拉斯·麦斯恩图施安德鲁·J·G·辛普森
Owner FUNDACAO OSWALDO CRUZ FIOCRUZ
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap